Several reports have shown that KLK6 is a promising biomarker of early diagnosis and unfavorable prognosis in several cancers, including ovarian cancer [32–36], colorectal cancer [37, 38], gastric cancer [39, 40], uterine cancer [41], lung cancer [42], and pancreatic cancer [43]. Here, KLK6 is linked to ovarian carcinoma.